Climb Bio (CLYM) Net Equity Issued and Repurchased (2020 - 2024)

Climb Bio (CLYM) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $41000.0 in Q4 2024.

• Quarterly Net Equity Issued and Repurchased fell 85.76% year-over-year to $41000.0 in Q4 2024, while the trailing twelve-month figure through Mar 2025 was $44.2 million (up 5067.13% YoY) and the FY2024 annual result came in at $11.0 million, up 1205.47% from the prior year.
• Net Equity Issued and Repurchased fell to $41000.0 in Q4 2024, from $2.3 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $93.8 million in Q3 2021 to a low of -$93.8 million in Q4 2021.
• A 4-year average of $3.9 million and a median of $105000.0 in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased plunged 2004.37% — and 2024, when it surged 174345.83%.
• Tracing CLYM's Net Equity Issued and Repurchased over 4 years: stood at $4.9 million in 2020, then sank by 2004.37% to -$93.8 million in 2021, then surged by 100.31% to $288000.0 in 2023, then slumped by 85.76% to $41000.0 in 2024.
• The last three Net Equity Issued and Repurchased figures came in at $41000.0 (Q4 2024), $2.3 million (Q3 2024), and $41.9 million (Q2 2024), per Business Quant data.